Hyperglycemia promotes Snail-induced epithelial–mesenchymal transition of gastric cancer via activating ENO1 expression

Xu, Xin; Chen, Bang; Zhu, Shaopu; Zhang, Jiawei; He, Xueling; Cao, Guodong; Chen, Bo

doi:10.1186/s12935-019-1075-8

Cited by 34 publications

(28 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies found that the upregulation of ENO1 was positively correlated with progression and poor prognosis in breast cancer, prostate cancer, thyroid carcinoma, hepatocellular carcinoma, cholangiocarcinoma, neuroblastoma, neuroendocrine tumors, lung cancer, and pancreatic cancer ( 4 , 9 – 13 ). Consistent to previous studies ( 2 , 4 , 14 – 23 ), more details are summarized in Supplementary Table 1 . Additionally, increased ENO1 expression has been observed in different types of drug-resistant cancer cells, suggesting the potential use of ENO1 as a biomarker for drug resistance and as a target for cancer therapy ( 5 ).…”

Section: Introductionsupporting

confidence: 66%

Enolase 1 Correlated With Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis

Yang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Enolase 1 (ENO1) is an oxidative stress protein expressed in endothelial cells. This study aimed to investigate the correlation of ENO1 with prognosis, tumor stage, and levels of tumor-infiltrating immune cells in multiple cancers. ENO1 expression and its influence on tumor stage and clinical prognosis were analyzed by UCSC Xena browser, Gene Expression Profiling Interactive Analysis (GEPIA), The Cancer Genome Atlas (TCGA), and GTEx Portal. The ENO1 mutation analysis was performed by cBio Portal, and demonstrated ENO1 mutation (1.8%) did not impact on tumor prognosis. The relationship between ENO1 expression and tumor immunity was analyzed by Tumor Immune Estimation Resource (TIMER) and GEPIA. The potential functions of ENO1 in pathways were investigated by Gene Set Enrichment Analysis. ENO1 expression was significantly different in tumor and corresponding normal tissues. ENO1 expression in multiple tumor tissues correlated with prognosis and stage. ENO1 showed correlation with immune infiltrates including B cells, CD8+ and CD4+ T cells, macrophages, neutrophils, and dendritic cells, and tumor purity. ENO1 was proved to be involved in DNA replication, cell cycle, apoptosis, glycolysis process, and other processes. These findings indicate that ENO1 is a potential prognostic biomarker that correlates with cancer progression immune infiltration.

show abstract

Section: Introductionsupporting

confidence: 66%

Enolase 1 Correlated With Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis

Yang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…vital role of ENO1 as an oncogene that promotes tumor progression. Emerging data indicate that ENO1 silencing inhibits tumor cell proliferation and invasion and reverses EMT progression [60][61][62][63] . In our study, we investigated HCC growth and metastasis in the presence and absence of ENO1.…”

Section: Discussionmentioning

confidence: 99%

“…These data correlated well with previous observations in lung cancer 25 , pancreatic cancer 26 , and colorectal cancer 59 , again supporting the vital role of ENO1 as an oncogene that promotes tumor progression. Emerging data indicate that ENO1 silencing inhibits tumor cell proliferation and invasion and reverses EMT progression 60 – 63 . In our study, we investigated HCC growth and metastasis in the presence and absence of ENO1.…”

Section: Discussionmentioning

confidence: 99%

Exosome-derived ENO1 regulates integrin α6β4 expression and promotes hepatocellular carcinoma growth and metastasis

et al. 2020

View full text Add to dashboard Cite

Alpha-enolase (ENO1) has been found to be dysregulated in several human malignancies, including hepatocellular carcinoma (HCC). Although the role of ENO1 as a glycolytic enzyme in HCC cells has been well characterized, little is known about the other roles of ENO1, especially exosome-derived ENO1, in regulating HCC progression. Here, we demonstrated that ENO1 is frequently upregulated in HCC cells or tissues, with even higher expression in highly metastatic HCC cells or metastatic tissues as well as in exosomes derived from highly metastatic sources. Moreover, ENO1 expression is associated with the tumor-node-metastasis (TNM) stage, differentiation grade and poor prognosis in HCC patients. Surprisingly, ENO1 can be transferred between HCC cells via exosome-mediated crosstalk, exhibiting an effect similar to that of ENO1 overexpression in HCC cells, which promoted the growth and metastasis of HCC cells with low ENO1 expression by upregulating integrin α6β4 expression and activating the FAK/Src-p38MAPK pathway. In summary, our data suggest that exosome-derived ENO1 is essential to promoting HCC growth, metastasis, and further patient deterioration. The findings from this study implicate a novel biomarker for the clinical evaluation of HCC progression, especially the prediction of HCC metastatic risk.

show abstract

“…Alpha-enolase is overexpressed in multiple human cancer types, contributing to increased glycolysis and tumor growth ( Altenberg and Greulich, 2004 ; Chang et al, 2006 ; He et al, 2007 ; Tsai et al, 2010 ; Capello et al, 2011 ; Song et al, 2014 ; Fu et al, 2015 ; Sun et al, 2017 , 2019 ; Zhan et al, 2017 ; Yin et al, 2018 ; Zhang et al, 2018 , 2020 ; Cheng et al, 2019 ; Ji et al, 2019 ; Qiao et al, 2019 ; Xu et al, 2019 ; Chen et al, 2020 ). ENO1 overexpression is often associated with anti-ENO1 autoantibody responses and may have prognostic and diagnostic value in certain cancers ( Table 1 ; Adamus et al, 1998 ; Tomaino et al, 2011 ; Pranay et al, 2013 ; Hsiao et al, 2015 ; Griggio et al, 2017 ; Zhang et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Alpha-Enolase: Emerging Tumor-Associated Antigen, Cancer Biomarker, and Oncotherapeutic Target

et al. 2021

View full text Add to dashboard Cite

Alpha-enolase, also known as enolase-1 (ENO1), is a glycolytic enzyme that “moonlights” as a plasminogen receptor in the cell surface, particularly in tumors, contributing to cancer cell proliferation, migration, invasion, and metastasis. ENO1 also promotes other oncogenic events, including protein-protein interactions that regulate glycolysis, activation of signaling pathways, and resistance to chemotherapy. ENO1 overexpression has been established in a broad range of human cancers and is often associated with poor prognosis. This increased expression is usually accompanied by the generation of anti-ENO1 autoantibodies in some cancer patients, making this protein a tumor associated antigen. These autoantibodies are common in patients with cancer associated retinopathy, where they exert pathogenic effects, and may be triggered by immunodominant peptides within the ENO1 sequence or by posttranslational modifications. ENO1 overexpression in multiple cancer types, localization in the tumor cell surface, and demonstrated targetability make this protein a promising cancer biomarker and therapeutic target. This mini-review summarizes our current knowledge of ENO1 functions in cancer and its growing potential as a cancer biomarker and guide for the development of novel anti-tumor treatments.

show abstract

Hyperglycemia promotes Snail-induced epithelial–mesenchymal transition of gastric cancer via activating ENO1 expression

Cited by 34 publications

References 45 publications

Enolase 1 Correlated With Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis

Enolase 1 Correlated With Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis

Exosome-derived ENO1 regulates integrin α6β4 expression and promotes hepatocellular carcinoma growth and metastasis

Alpha-Enolase: Emerging Tumor-Associated Antigen, Cancer Biomarker, and Oncotherapeutic Target

Contact Info

Product

Resources

About